Reviva Pharmaceuticals Holdings, Inc. (RVPH)
NASDAQ: RVPH · Real-Time Price · USD
0.7768
-0.0429 (-5.23%)
At close: May 12, 2025, 4:00 PM
0.7600
-0.0168 (-2.16%)
After-hours: May 12, 2025, 7:52 PM EDT
RVPH Employees
Reviva Pharmaceuticals Holdings had 14 employees as of December 31, 2024. The number of employees decreased by 1 or -6.67% compared to the previous year.
Employees
14
Change (1Y)
-1
Growth (1Y)
-6.67%
Revenue / Employee
n/a
Profits / Employee
-$2,137,057
Market Cap
36.31M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RVPH News
- 6 weeks ago - Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress - GlobeNewsWire
- 3 months ago - Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 3 months ago - Reviva to Participate in the 2025 BIO CEO & Investor Conference - GlobeNewsWire
- 4 months ago - Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit - GlobeNewsWire
- 5 months ago - Reviva Announces Proposed Public Offering - GlobeNewsWire
- 5 months ago - Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low - Seeking Alpha
- 6 months ago - Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 6 months ago - Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024 - GlobeNewsWire